Paul Hastings has advised Crealights Technology Co., Ltd. Crealights Technology Co., Ltd., a provider of optoelectronic interconnection products, has completed a global offering and listing on...
Crealights Completes US$196 Million Hong Kong IPO and Global Offering
Shenzhen Creality 3D Technology’s HK$1.38 Billion IPO on Hong Kong Stock Exchange
Paul Hastings (Hong Kong) LLP has advised Shenzhen Creality 3D Technology Co. Ltd. on its global offering and Main Board listing. Shenzhen Creality 3D Technology Co....
Novosense Microelectronics Raises HK$2.2 Billion in Hong Kong IPO and Global Offering
Paul Hastings has advised Suzhou Novosense Microelectronics Co., Ltd.; Norton Rose Fulbright advised the joint sponsors. Suzhou Novosense Microelectronics Co., Ltd. has completed a global offering...
Haiwei Electronic Completes HK$440 Million Global Offering and Hong Kong Listing
Paul Hastings has advised Hebei Haiwei Electronic New Material Technology Co., Ltd. Hebei Haiwei Electronic New Material Technology Co., Ltd. has successfully completed a global offering...
Ningbo Joyson Electronic Corp Completes US$437 Million Global Offering and Hong Kong Listing
Clifford Chance and Commerce & Finance Law Offices have advised Ningbo Joyson Electronic Corp. Jincheng Tongda & Neal Law Firm counselled the issuer on PRC data...
Fortior Tech’s HK$2.2 Billion Hong Kong IPO and Global Offering
Paul Hastings has advised Fortior Technology (Shenzhen) Co., Ltd. Fortior Technology (Shenzhen) Co., Ltd. has successfully completed a global offering and listing on the Main Board...
Zhejiang Hangke Technology Incorporated Company’s Global Depositary Receipts Offering and Listing
Clifford Chance advised CLSA Limited and Huatai Financial Holdings (Hong Kong) Limited. Allen & Overy advised Zhejiang HangKe Technology Incorporated Company. CLSA Limited and Huatai Financial...
Bilibili Inc.’s $2.6 Billion Secondary Listing
Walkers acted as Cayman Islands counsel to Bilibili Inc. in connection with its US$2.6 billion global offering of 25 million shares on the Main Board of...
SciClone Pharmaceuticals’ Hong Kong Initial Public Offering And Listing
Clifford Chance, Maples and Calder JunHe advised SciClone Pharmaceuticals on its US$281 million initial public offering and listing on the main board of the Hong Kong...